Biocon Limited

Biocon Limited

Biocon Limited has announced the publication of two clinical studies supporting the effectiveness of Yesafili, a biosimilar to Eylea, in the treatment of diabetic macular edema. The studies were published in the British Journal of Ophthalmology and Expert Opinion on Biological Therapy, and demonstrate comparable safety, efficacy, and immunogenicity profiles between participants who continued treatment with MYL-1701P and those who switched from reference aflibercept.

Biocon Limited

Biocon Limited has informed the Exchange about Copy of Newspaper Publication regarding the 48th Annual General Meeting (AGM) to be held through Video Conferencing or Other Audio Visual Means (VC/OAVM) on August 08, 2026, along with the Integrated Annual Report for the FY 2025-26.

Biocon Limited

Biocon Limited has informed the Exchange regarding allotment of 87,86,362 securities pursuant to Preferential Issue at its meeting held on Jun 29, 2026, as consideration for the acquisition of equity shares of Biocon Biologics Limited.

Biocon Limited

Biocon Limited has informed the Exchange about the acquisition of equity shares of Biocon Biologics Limited and allotment of equity shares of Biocon Limited on preferential basis. The Company has completed the acquisition of 1,15,36,956 equity shares of Biocon Biologics Limited from 127 selling shareholders. The Company has also issued and allotted 87,86,362 equity shares of Biocon Limited to the 127 selling shareholders as consideration for the acquisition. The equity shares allotted shall rank pari-passu with the existing equity shares of the Company.

Biocon Limited

Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Biocon Limited

Biocon Limited announced that its partner, Duopharma Biotech, secured multiple insulin tenders from Malaysia's Ministry of Health, valued at over MYR 225 million. Biocon's Malaysian subsidiary will supply short-acting recombinant human insulin, insulin glargine, and insulin aspart under these contracts, which include a three-year human insulin agreement and two-year agreements for insulin glargine and aspart. This reinforces Biocon's commitment to diabetes care in Malaysia, ensuring continued access to high-quality, cost-effective insulin therapies and strengthening its market presence.

Biocon Limited

Biocon Limited has issued a communication to its shareholders detailing the deduction of Tax at Source (TDS) on the final dividend for the financial year 2025-26. The Board had recommended a final dividend of 10% (Re. 0.50 per equity share) on May 7, 2026, which is subject to shareholder approval at the AGM on August 6, 2026, with July 3, 2026, as the record date. The notice outlines the applicable TDS provisions, varying rates based on shareholder categories and residential status, and requests shareholders to update their PAN and other relevant details to ensure correct tax deduction or exemption.